Timber Pharmaceuticals (TMBR +0.5%) receives a formal notice of allowance from the U.S. Patent and Trademark Office for the patent application covering its pharmaceutical tetracycline compositions for dermatological use.

Timber previously announced its intention to evaluate its proprietary topical programs, BPX-01 and BPX-04 and believes the expansion of claims for this patent will further protect these assets.

U.S. Patent Application No.: 16/514,459.


Source link

Comments to: Timber Pharmaceuticals bags notice of allowance from USPTO for BPX-01 and BPX-04 (NYSEMKT:TMBR)

Your email address will not be published. Required fields are marked *

Attach images - Only PNG, JPG, JPEG and GIF are supported.


Welcome to Typer

Brief and amiable onboarding is the first thing a new user sees in the theme.
Join Typer
Registration is closed.